Hendrik Peter Scholl, Chief Medical Officer at Belite Bio, sold BLTE on Jun 16, 2026
Data as of Oct 16
- Traded
- Jun 16, 2026
- Disclosed
- Jun 17, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
BLTE since disclosure
−3.7%
after the sale
Similar stocks (XLV) since disclosure
+17.3%
XLV — its sector index fund
Change in closing price from Jun 17, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.
Other trades in the same filing
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$438Kdisclosed Jun 17 · filed 1 day after the trade
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$150Kdisclosed Jun 17 · filed 1 day after the trade
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$14.2Kdisclosed Jun 17 · filed 1 day after the trade
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$283Kdisclosed Jun 17 · filed 1 day after the trade
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$64Kdisclosed Jun 17 · filed 1 day after the trade
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$108Kdisclosed Jun 17 · filed 1 day after the trade
- ▼ SELLHendrik Peter Scholl Chief Medical OfficerBLTE Belite Bio, Inc$272Kdisclosed Jun 17 · filed 1 day after the trade